Skip to content

68Ga-DOTA-TATE PET/MR somatostatin receptor imaging combined with serum TSHR antibodies and IGF-1R for clinical diagnosis of staging in Graves’ ophthalmopathy

68Ga-DOTA-TATE PET/MR somatostatin receptor imaging combined with serum TSHR antibodies and IGF-1R for clinical diagnosis of staging in Graves’ ophthalmopathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040433
Enrollment
Unknown
Registered
2020-11-28
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves’ ophthalmopathy

Interventions

Gold Standard:Clinical outcomes
Index test:68Ga-DOTATATE&#32
SUVmax&#32
&#32
serum&#32
TSHR&#32
IGF-1R&#32

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 14 to 65 years old; 2. Outpatients or inpatients in this hospital; 3. Frueh standard entry screening: 1) Patients have a history of thyroid disease, exophthalmos, protrusion >=20 mm, eyelid retraction, palpebral fissure enlargement by more than 11 mm, extraocular muscle involvement, at least one extraocular muscle is restricted For sexual lesions, CT examination showed that the extraocular muscles of one or both eyes were thickened; 2) 3 signs of exophthalmos/eyelid retraction/extraocular muscle involvement appeared, and at least 2 signs were bilateral; 3) exophthalmos/eyelid retraction /CT examination found that the extraocular muscles were thickened, and at least 1 of the 3 signs had more than 2 signs; 5. Patients need to agree to participate in the experiment and agree to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Acute systemic diseases and electrolyte disorders; 2. Pregnant or lactating women; 3. Other patients who are not suitable for participating in the experiment (including PET/MR contraindications); 4. Patients who cannot be followed up as required during the study period.

Design outcomes

Primary

MeasureTime frame
SUVmax;serum TSHR;serum IGF-IR;

Countries

China

Contacts

Public ContactXiaotian Xia

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST)

xiaotian_xia@hust.edu.cn+86 13476040934

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026